CAJ | 학술논문

目的评估卵巢癌细胞减瘤术后腹腔热灌注化疗的临床疗效和安全性.方法按制定的标准选取公开发表的文献,分别记录手术的种类和方法、腹腔热灌注化疗的方式、并发症、病死率、住院时间和生存时间等,并对化疗药物剂量、热灌注的方法、化疗持续时间等进行描述.结果本荟萃分析最终有14篇符合标准的文献入选,7项研究表明进行了肿瘤根治术后腹腔热灌注化疗的患者预后较好.原发性卵巢癌和复发性卵巢癌患者治疗后的中位生存期为22个月到54个月；中位无病生存期为10个月到26个月.卵巢癌细胞减瘤术后腹腔热灌注化疗的严重并发症发生率为5％～ 36％；中位病死率3％(0％～10％),并发症发生率和病死率均较低.结论卵巢癌患者细胞减瘤术后腹腔热灌注化疗是可以选择的一种良好的治疗方式,临床应用安全可行.
목적 평고란소암세포감류술후복강열관주화료적림상료효화안전성.방법 안제정적표준선취공개발표적문헌,분별기록수술적충류화방법、복강열관주화료적방식、병발증、병사솔、주원시간화생존시간등,병대화료약물제량、열관주적방법、화료지속시간등진행묘술.결과 본회췌분석최종유14편부합표준적문헌입선,7항연구표명진행료종류근치술후복강열관주화료적환자예후교호.원발성란소암화복발성란소암환자치료후적중위생존기위22개월도54개월；중위무병생존기위10개월도26개월.란소암세포감류술후복강열관주화료적엄중병발증발생솔위5％～ 36％；중위병사솔3％(0％～10％),병발증발생솔화병사솔균교저.결론 란소암환자세포감류술후복강열관주화료시가이선택적일충량호적치료방식,림상응용안전가행.
Objective To analyze the clinical efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy (HIPC) after cytoreductive surgery for ovarian carcinoma.Methods Based on the pre-designed criteria,the articles published were searched and recorded for data on types and options of surgery,use of HIPC,complications,mortalities,hospital stays and survival time.The dosage of chemotherapy agents,method of hyperthermic perfusion and duration of chemotherapy were also described.Results Fourteen articles were finally included in this meta-analysis.Among these,7 studies showed favorable patient outcomes with HIPC after radical tumor resection.The median survival time and median disease-free survival for primary ovarian carcinoma and relapsed ovarian carcinoma ranged from 22 to 54months and 10 to 26 months,respectively.The incidence of serious complications with HIPC after cytoreductive surgery ranged from 5％ to 36％,with the median mortality being 3％ (0％ -10％ ).The incidence of complications and the mortality were low.Conclusion HIPC after cytoreductive surgery may be used as a promising treatment which is clinically safe and feasible.